{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:13:38Z","timestamp":1789010018451,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["CH03\/003"],"award-info":[{"award-number":["CH03\/003"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1111\/jth.15899","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T08:49:59Z","timestamp":1665737399000},"page":"2939-2952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Btk inhibitor AB\u201095\u2010LH34 potently inhibits atherosclerotic plaque\u2013induced thrombus formation and platelet procoagulant activity"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-2032","authenticated-orcid":false,"given":"Christopher W.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-5192","authenticated-orcid":false,"given":"Maan H.","family":"Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7942-8127","authenticated-orcid":false,"given":"Lourdes","family":"Garcia\u2010Quintanilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1885-6686","authenticated-orcid":false,"given":"Kieran","family":"Rookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-151X","authenticated-orcid":false,"given":"Helena","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-2130","authenticated-orcid":false,"given":"Natalie S.","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-7423","authenticated-orcid":false,"given":"Steve P.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4843-2975","authenticated-orcid":false,"given":"Phillip L.R.","family":"Nicolson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7048-7764","authenticated-orcid":false,"given":"Mark R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15899_bb0010","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long\u2010term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15899_bb0015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15899_bb0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15899_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09537104.2020.1763731","article-title":"Novel antiplatelet targets in the treatment of acute coronary syndromes","volume":"32","author":"Alenazy","year":"2021","journal-title":"Platelets"},{"key":"10.1111\/jth.15899_bb0030","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1538-7836.2011.04328.x","article-title":"Genetic and antibody\u2010induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl3\u2010induced thrombosis","volume":"9","author":"Bender","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15899_bb0035","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2005-10-4244","article-title":"Thrombin overcomes the thrombosis defect associated with platelet GPVI\/FcR\u03b3 deficiency","volume":"107","author":"Mangin","year":"2006","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1538-7836.2009.03666.x","article-title":"Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization","volume":"8","author":"Hechler","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15899_bb0045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1538-7836.2008.03186.x","article-title":"Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model","volume":"7","author":"Kuijpers","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15899_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2004.12.037","article-title":"Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions","volume":"181","author":"Cosemans","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1111\/jth.15899_bb0055","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/jth.12334","article-title":"An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean families","volume":"11","author":"Matus","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15899_bb0060","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2003-03-0717","article-title":"The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion","volume":"102","author":"Kato","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0065","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2009-03-213504","article-title":"Absence of collagen\u2010induced platelet activation caused by compound heterozygous GPVI mutations","volume":"114","author":"Dumont","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0070","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1538-7836.2009.03520.x","article-title":"A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder","volume":"7","author":"Hermans","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15899_bb0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.193.4.459","article-title":"Long\u2010term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice","volume":"193","author":"Nieswandt","year":"2001","journal-title":"J Exp Med"},{"key":"10.1111\/jth.15899_bb0080","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (dimeric glycoprotein VI\u2010fc) specifically and efficiently inhibited collagen\u2010induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.15899_bb0085","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/jcph.1616","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of glenzocimab (ACT017) a glycoprotein VI inhibitor of collagen\u2010induced platelet aggregation","volume":"60","author":"Renaud","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jth.15899_bb0090","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2017-09-808808","article-title":"Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque\u2010triggered thrombus formation in humans","volume":"131","author":"Busygina","year":"2018","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0095","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/09537104.2020.1775189","article-title":"A rationale for blocking thromboinflammation in COVID\u201019 with Btk inhibitors","volume":"31","author":"Nicolson","year":"2020","journal-title":"Platelets"},{"key":"10.1111\/jth.15899_bb0100","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis","volume":"184","author":"Brown","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15899_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by bruton tyrosine kinase\u2010inhibitors: dependency on drug type and disease","volume":"13","author":"von Hundelshausen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1111\/jth.15899_bb0110","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr Biol"},{"key":"10.1111\/jth.15899_bb0115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2019.218545","article-title":"Low\u2010dose Btk inhibitors selectively block platelet activation by CLEC\u20102","volume":"106","author":"Nicolson","year":"2021","journal-title":"Haematologica"},{"key":"10.1111\/jth.15899_bb0120","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/ATVBAHA.115.306130","article-title":"Ibrutinib inhibits platelet integrin \u03b1IIb\u03b23 outside\u2010in signaling and thrombus stability but not adhesion to collagen","volume":"35","author":"Bye","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.15899_bb0125","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI\u201032765 blocks B\u2010cell activation and is efficacious in models of autoimmune disease and B\u2010cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/jth.15899_bb0130","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and Pharmacodynamic modeling of the BTK inhibitor Evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J Immunol"},{"key":"10.1111\/jth.15899_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128549","article-title":"Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors","volume":"60","author":"Ma","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/jth.15899_bb0140","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1021\/acs.jmedchem.9b00794","article-title":"Discovery of Evobrutinib: an Oral, potent, and highly selective, covalent Bruton's tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases","volume":"62","author":"Caldwell","year":"2019","journal-title":"J Med Chem"},{"key":"10.1111\/jth.15899_bb0145","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo\u2010controlled trial of an Oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15899_bb0150","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial","volume":"14","author":"Kaul","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1111\/jth.15899_bb0155","unstructured":"Maurer M. The Bruton's tyrosine kinase inhibitor remibrutinib (LOU064) in chronic spontaneous urticaria: top\u2010line results of a phase 2b dose\u2010finding study. D3T01.3, EADV Congress 2021, 29 Sept\u20132 Oct."},{"key":"10.1111\/jth.15899_bb0160","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton's tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"key":"10.1111\/jth.15899_bb0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/09537104.2020.1748588","article-title":"An adaptable analysis workflow for characterization of platelet spreading and morphology","volume":"32","author":"Pike","year":"2021","journal-title":"Platelets"},{"key":"10.1111\/jth.15899_bb0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/jth.15899_bb0175","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3324\/haematol.2018.193391","article-title":"Inhibition of Btk by Btk\u2010specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI","volume":"103","author":"Nicolson","year":"2018","journal-title":"Haematologica"},{"key":"10.1111\/jth.15899_bb0180","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0008-6363(98)00306-X","article-title":"Collagen\u2013platelet interaction: Gly\u2010pro\u2010Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen1","volume":"41","author":"Knight","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1111\/jth.15899_bb0185","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1096\/fj.04-2748com","article-title":"Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI","volume":"19","author":"Penz","year":"2005","journal-title":"FASEB J"},{"key":"10.1111\/jth.15899_bb0190","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","article-title":"A 2\u2010step mechanism of arterial thrombus formation induced by human atherosclerotic plaques","volume":"55","author":"Reininger","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.15899_bb0195","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00395-008-0722-3","article-title":"Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo","volume":"103","author":"Schulz","year":"2008","journal-title":"Basic Res Cardiol"},{"key":"10.1111\/jth.15899_bb0200","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.jacc.2015.03.573","article-title":"Differential inhibition of human atherosclerotic plaque\u2010induced platelet activation by dimeric GPVI\u2010fc and anti\u2010GPVI antibodies: functional and imaging studies","volume":"65","author":"Jamasbi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.15899_bb0205","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1161\/ATVBAHA.120.314301","article-title":"Pharmacological blockade of glycoprotein VI promotes thrombus disaggregation in the absence of thrombin","volume":"40","author":"Ahmed","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.15899_bb0210","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor\u2010dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0215","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-0039-1677744","article-title":"Optimizing platelet GPVI inhibition versus haemostatic impairment by the BTK inhibitors ibrutinib, acalabrutinib, ONO\/GS\u20104059, BGB\u20103111 and evobrutinib","volume":"119","author":"Denzinger","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15899_bb0220","article-title":"Differential impact of BTK active site inhibitors on the conformational state of full\u2010length BTK","volume":"9","author":"Joseph","year":"2020"},{"key":"10.1111\/jth.15899_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell\u2013 and myeloid cell\u2013mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1111\/jth.15899_bb0230","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of fc receptor but not B\u2010cell receptor signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1111\/jth.15899_bb0235","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1021\/acsmedchemlett.9b00317","article-title":"Design of Potent and Selective Covalent Inhibitors of Bruton's tyrosine kinase targeting an inactive conformation","volume":"10","author":"Pulz","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1111\/jth.15899_bb0240","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1111\/jth.15899_bb0245","doi-asserted-by":"crossref","first-page":"749022","DOI":"10.3389\/fcvm.2021.749022","article-title":"Effects of the Btk\u2010inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) with varying Btk selectivity over Tec on platelet aggregation and in vitro bleeding time","volume":"8","author":"Duan","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1111\/jth.15899_bb0250","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib","volume":"1","author":"Bye","year":"2017","journal-title":"Blood Adv"},{"key":"10.1111\/jth.15899_bb0255","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1096\/fj.02-0381fje","article-title":"Complementary roles of platelet glycoprotein VI and integrin \u03b12\u03b21 in collagen\u2010induced thrombus formation in flowing whole blood ex vivo","volume":"17","author":"Kuijpers","year":"2003","journal-title":"FASEB J"},{"key":"10.1111\/jth.15899_bb0260","doi-asserted-by":"crossref","first-page":"19781","DOI":"10.1074\/jbc.R109.013219","article-title":"Structural insights into the interactions between platelet receptors and Fibrillar collagen *","volume":"284","author":"Herr","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15899_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-1940fje","article-title":"Adhesion of human and mouse platelets to collagen under shear: a unifying model","volume":"19","author":"Auger","year":"2005","journal-title":"FASEB J"},{"key":"10.1111\/jth.15899_bb0270","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood-2017-05-787259","article-title":"Procoagulant platelets: generation, function, and therapeutic targeting in thrombosis","volume":"130","author":"Agbani","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0275","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood-2008-07-171611","article-title":"Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation","volume":"113","author":"Braun","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0280","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1161\/CIRCULATIONAHA.114.015036","article-title":"Coordinated membrane ballooning and procoagulant spreading in human platelets","volume":"132","author":"Agbani","year":"2015","journal-title":"Circulation"},{"key":"10.1111\/jth.15899_bb0285","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.V90.7.2615","article-title":"Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase\u2010dependent Ca2+ responses","volume":"90","author":"Heemskerk","year":"1997","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-02933-4","article-title":"Membrane ballooning in aggregated platelets is synchronised and mediates a surge in microvesiculation","volume":"7","author":"Agbani","year":"2017","journal-title":"Sci Rep"},{"key":"10.1111\/jth.15899_bb0295","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1182\/blood-2015-08-663005","article-title":"Necrotic platelets provide a procoagulant surface during thrombosis","volume":"126","author":"Hua","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0300","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/j.1538-7836.2007.02691.x","article-title":"Coated\u2010platelet levels are influenced by smoking, aspirin, and selective serotonin reuptake inhibitors","volume":"5","author":"Prodan","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15899_bb0305","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/01.CIR.99.14.1780","article-title":"Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques","volume":"99","author":"Badimon","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/jth.15899_bb0310","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1538-7836.2004.00551.x","article-title":"Rapid generation of thrombin by atheroma and platelets","volume":"2","author":"Niemetz","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15899_bb0315","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding\u2010related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"10.1111\/jth.15899_bb0320","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"key":"10.1111\/jth.15899_bb0325","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long\u2010term follow\u2010up of MCL patients treated with single\u2010agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15899_bb0330","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single\u2010agent ibrutinib","volume":"178","author":"Jones","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15899_bb0335","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: a randomized, double\u2010blind, Phase II Trial","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1111\/jth.15899_bb0340","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC\u20100853) in systemic lupus erythematosus: results of a phase II, randomized, double\u2010blind, placebo\u2010controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1111\/jth.15899_bb0345","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an Oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15899","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622183856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622183856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:36:34Z","timestamp":1761536194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622183856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1538783622183856"],"URL":"https:\/\/doi.org\/10.1111\/jth.15899","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Btk inhibitor AB\u201095\u2010LH34 potently inhibits atherosclerotic plaque\u2013induced thrombus formation and platelet procoagulant activity","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}